Biotalk Episode 34: 2026 Q1 Report: Global Trends in Biopharma Transactions

During Episode 34 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q1 Report: Global Trends in Biopharma Transactions, covering capital markets, strategic deals, and regional trends.   Market Overview: Q1 2026 was defined by continuity rather than reversal. Licensing tied a three-year high, M&A recorded its strongest first quarter ever, and U.S. capital markets reopened meaningfully with the return of biotech IPOs. China’s dominance in global licensing expanded further, while Europe and the UK remained challenged.  Strategic Transactions: Global licensing reached approximately $87B across 57 transactions, with greater than 90% of deal value concentrated in early-stage programs. China-based sellers drove 66% of global licensing value -up from 48% in full-year 2025 -with average deal values rising to ~$1.9B and upfront payments more than doubling sequentially to ~$179M.  M&A delivered the strongest Q1 on record at ~$50B, a 58% year-over-year increase. U.S.-based sellers accounted for 95% of deal value, with Phase 2 assets emerging as the leading contributor at 38% and oncology rebounding to 42% of deal value.  Capital Markets: Six U.S. biotech IPOs raised ~$1.8B -exceeding the full-year 2025 total. Venture financing surged 44% quarter-over-quarter to $5B, and reductions in force hit a three-year low of 34. In contrast, European venture financing fell 63% to $613M, with capital concentrated in a handful of late-stage financings.  Outlook: Strategic dealmaking remains strong, and capital markets are increasingly open, but deal structures will continue to favor milestone-heavy economics. China’s structural role in global licensing and venture financing will shape partnership and exit strategies across the remaining quarters of 2026.